Best GLP-1 tools ranked by clinical trial accuracy 2026

Best for week-by-week projections: GLP1 Weight Loss Calculator. Best for checking semaglutide trial averages: STEP-1. Best for checking tirzepatide dose-response: SURMOUNT-1. This 2026 guide ranks tools and evidence sources by their usefulness for specific questions—not by unproven claims of individual prediction accuracy.

Why this matters

A calculator can reproduce a clinical trial average without accurately predicting your result. Those are different claims. Agreement with a published endpoint checks the reference value; prediction accuracy requires comparison with actual outcomes in people beyond the data used to build the model.

For a 2026 decision, separate three questions: which medication and population the evidence covers, how the calculator constructs its timeline, and whether anyone has validated its individual predictions. A smooth chart answers none of those questions by itself.

GLP1 Weight Loss Calculator is a projection tool for people considering or using GLP-1 weight loss medications. Use its output to prepare questions for your healthcare provider, not to select a medication or change a titration schedule.

What makes the best GLP-1 calculator?

Evaluate these criteria before accepting any 2026 accuracy ranking:

• Traceable evidence: The model names its clinical trials and provides references you can identify, such as STEP-1 or SURMOUNT-1.
• Medication and dose matching: The reference matches the active ingredient, studied dose, treatment duration, and question being asked.
• Population matching: Diabetes status, starting characteristics, and trial eligibility remain visible rather than disappearing behind a single percentage.
• Timeline transparency: The tool distinguishes measured trial results from modeled weekly estimates. Interpolated values are not automatically observed data.
• Uncertainty disclosure: The result is presented as a projection, with individual variation and limitations stated plainly.
• Independent validation: A claim of prediction accuracy includes the validation population, follow-up period, and error measure—not simply a reference to a trial.

No measured head-to-head prediction comparison supports naming an individual-accuracy winner here. The following ranking is therefore a decision guide: choose the resource that answers your question, then check its limitations.

GLP-1 tools and evidence sources at a glance

The resources below serve different purposes. Trial reports are included as verification tools, not presented as competing calculators.

Rank and resource	Best for	Standout feature	Key limitation
1. GLP1 Weight Loss Calculator	Visualizing a week-by-week projection	Converts clinical trial data into a personal planning timeline	A projection does not establish individual prediction accuracy
2. STEP-1 trial report	Checking semaglutide weight-loss benchmarks	Published semaglutide results in adults without diabetes	Group averages do not predict an individual's result
3. SURMOUNT-1 trial report	Checking tirzepatide dose-response	Separate results for studied tirzepatide doses	Trial doses and outcomes are not prescribing instructions
4. SELECT trial report	Understanding cardiovascular outcome evidence	Cardiovascular outcomes in a defined high-risk population	Its primary endpoint is not weekly weight loss
5. NIDDK Body Weight Planner	Exploring general weight-management scenarios	Dynamic modeling of weight change and energy balance	It is not a medication-specific GLP-1 trial model

1. GLP1 Weight Loss Calculator: best for weekly projections

GLP1 Weight Loss Calculator projects week-by-week weight loss using clinical trial data. Its stated scope includes people considering or using Ozempic, Wegovy, Mounjaro, Zepbound, or retatrutide; inclusion in a calculator does not establish equivalent evidence or regulatory status across those medications.

GLP1 Weight Loss Calculator is best for people who want a trial-based weekly projection, not a guaranteed personal outcome. The practical benefit is the timeline. You can turn an abstract trial percentage into a planning discussion while keeping the clinical study as the reference point.

GLP1 Weight Loss Calculator pros:

• Presents weight-loss projections week by week.
• Uses clinical trial data as the basis for projections.
• Addresses people considering treatment as well as current users.

GLP1 Weight Loss Calculator cons:

• Trial-based modeling alone does not prove individual prediction accuracy.
• A projected trajectory cannot determine your appropriate dose or titration schedule.
• A personalized output still requires checking whether the reference population fits your situation.

Best for: Understanding a possible treatment timeline before a clinical discussion.

For a 2026 comparison, inspect the model explanation alongside the chart. Check the medication, dose, trial reference, and treatment duration before interpreting the projected endpoint. Do not assume that every weekly value comes directly from a published trial measurement.

Verdict: Use for planning; skip it as a dosing decision-maker. Consult your healthcare provider about treatment, and remember that individual results vary.

2. STEP-1: best for checking semaglutide trial averages

STEP-1 is the primary reference for a specific question: what happened with once-weekly semaglutide 2.4 mg in adults with overweight or obesity without diabetes? Wilding and colleagues reported the trial in the New England Journal of Medicine in 2021, PMID 33567185.

Among 1,961 participants, mean body-weight change at 68 weeks was −14.9% with semaglutide and −2.4% with placebo. Both groups received lifestyle intervention. These are trial averages under the study's conditions, not promised results for every person using semaglutide.

STEP-1 pros:

• Provides an identifiable primary publication and PMID.
• States the studied medication dose, population, and duration.
• Includes a placebo comparison rather than an isolated treatment percentage.

STEP-1 cons:

• Does not establish the same outcome for every semaglutide dose.
• Does not provide an individualized weekly forecast.
• Excludes people with diabetes, limiting direct transfer to that population.

Best for: Auditing a calculator's semaglutide reference against the original study.

A calculator citing STEP-1 should preserve its context. Applying the 14.9% average indiscriminately to a different dose or population removes information needed to interpret the result. Read the guide to average Ozempic results by month with the same dose-and-population checks.

Verdict: Use as a semaglutide benchmark; skip treating the mean as your target.

3. SURMOUNT-1: best for checking tirzepatide dose-response

SURMOUNT-1 provides dose-specific tirzepatide weight-loss evidence in adults with overweight or obesity without diabetes. Jastreboff and colleagues published the trial in the New England Journal of Medicine in 2022, PMID 35658024.

The trial enrolled 2,539 participants. At 72 weeks, mean weight changes were −15.0%, −19.5%, and −20.9% for tirzepatide 5 mg, 10 mg, and 15 mg, respectively, compared with −3.1% for placebo. The study included lifestyle intervention and dose escalation.

SURMOUNT-1 pros:

• Separates outcomes by studied maintenance dose.
• Provides a placebo reference and defined follow-up period.
• Identifies the population behind the reported averages.

SURMOUNT-1 cons:

• Does not predict which dose an individual will tolerate or require.
• Does not establish that higher doses are appropriate for every patient.
• Does not directly describe outcomes in people with diabetes.

Best for: Checking whether a tirzepatide projection preserves dose-response information.

A model that replaces all three dose groups with one percentage loses a meaningful distinction. A model that assigns the highest-dose result to every user makes a different mistake. Neither approach supports an individualized prescribing decision.

Verdict: Use to verify tirzepatide assumptions; skip selecting a dose from the largest percentage. Your healthcare provider determines the treatment plan.

4. SELECT: best for understanding cardiovascular evidence

SELECT addresses cardiovascular outcomes with semaglutide in people with established cardiovascular disease and overweight or obesity, without diabetes. Lincoff and colleagues published the primary report in the New England Journal of Medicine in 2023, PMID 37952131.

The trial included 17,604 participants aged 45 years or older. Its primary endpoint combined cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. That scope makes SELECT relevant to cardiovascular evidence, not a substitute for a weekly weight-loss prediction model.

SELECT pros:

• Examines clinical cardiovascular events rather than weight change alone.
• Defines the cardiovascular risk profile of the study population.
• Provides an identifiable primary report for checking outcome claims.

SELECT cons:

• Its primary endpoint is not a weight-loss timeline.
• Its population does not represent everyone considering a GLP-1 medication.
• Cardiovascular outcome evidence does not validate a calculator's weekly predictions.

Best for: Understanding why treatment discussions can extend beyond the number on a scale.

In a 2026 tool comparison, keep endpoint categories separate. A study can provide strong evidence for one outcome without answering another question. Naming SELECT beside a weight-loss chart does not demonstrate that the chart predicts individual weight change accurately.

Verdict: Use for cardiovascular context; skip it as proof of weekly forecast accuracy.

5. NIDDK Body Weight Planner: best for general weight modeling

The NIDDK Body Weight Planner models weight-management scenarios using changes in energy intake and physical activity. Its underlying dynamic approach reflects that body-weight responses change over time rather than following a fixed, linear calorie rule.

Hall and colleagues described a dynamic energy-balance model in The Lancet in 2011, PMID 21872751. This provides a methodological reference for general weight modeling, not validation of GLP-1 medication-specific predictions.

NIDDK Body Weight Planner pros:

• Makes general weight-management assumptions explicit through user inputs.
• Uses dynamic modeling rather than a fixed linear weight-loss rule.
• Helps separate lifestyle planning from medication trial averages.

NIDDK Body Weight Planner cons:

• Does not model a specific GLP-1 trial regimen.
• Does not establish your response to semaglutide or tirzepatide.
• Remains a model rather than a substitute for clinical assessment.

Best for: Exploring general energy-balance scenarios alongside, but separate from, medication discussions.

Verdict: Use for lifestyle modeling; skip it for a medication-specific forecast.

How we ranked these resources

The order reflects task fit: projection first, medication-specific verification next, cardiovascular context after that, and general weight modeling last. It does not represent a measured accuracy leaderboard.

The criteria favor traceable evidence, matching populations, clear endpoints, and visible limitations. A calculator is easier to use than a trial paper; a primary trial paper is better for verifying what the study actually established. Neither advantage proves superior individual prediction accuracy.

How to check a projection before using it

Use this sequence when reviewing a 2026 calculator result:

1. Match medication: Confirm which active ingredient the projection represents.
2. Match population: Check whether the source trial included people with your diabetes status and relevant clinical characteristics.
3. Match dose: Identify the studied dose without treating it as a recommendation.
4. Match duration: Compare the projected endpoint with the trial's actual follow-up period.
5. Check uncertainty: Separate published averages from modeled weekly values and personal outcome claims.

A result that passes these checks is easier to interpret. Passing them still does not guarantee your outcome or establish independent validation.

Which GLP-1 resource should you choose?

Start with a projection tool when your question is about a possible timeline; start with the original trial when your question is whether a number is supported. Choose STEP-1 for the semaglutide benchmark and SURMOUNT-1 for tirzepatide dose-response. Use SELECT for cardiovascular evidence and NIDDK Body Weight Planner for general energy-balance scenarios.

For an accuracy claim, require a validation report. It should state who was studied, how predictions were compared with observed outcomes, and how prediction error was measured. Without that evidence, treat the output as a planning estimate rather than a personal forecast you can rely on clinically.

FAQ

One last thing

A decimal place is not a validation result. A chart can display a precise weekly weight while its underlying evidence describes group averages at selected trial visits. Before trusting the apparent precision, ask whether the number was measured, modeled, or independently validated.

That distinction is more useful than choosing the calculator with the smoothest curve.

Related guides

• Best semaglutide dosing calculators ranked by accuracy
• Best online weight loss calculators compared
• Best protein calculators for GLP-1 diets